UBS Oncology Impact Fund L.P., 10% Owner at iTeos Therapeutics, Inc. (ITOS), sold 117,152 shares at $27.09 ($3.2M) on 2021-09-27, disclosed to the SEC on 2021-09-27.
Open-market sale of $3.2M ITOS by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $27.96 | 60,600 | $1.7M | 52.3% |
| 2 | $28.38 | 1,200 | $34K | 1.1% |
| 3 | $27.81 | 8,221 | $229K | 7.1% |
| 4 | $27.81 | 8,221 | $229K | 7.1% |
| 5 | $27.09 | 19,455 | $527K | 16.3% |
| 6 | $27.09 | 19,455 |
| $527K |
| 16.3% |
| Total | $27.65 avg | 117,152 | $3.2M | 100% |
| Filing → |
| HOWL | SELL | 2025-10-29 | $685K | — | Filing → |
| CGEM | SELL | 2021-09-02 | $1.3M | — | Filing → |
| HARP | SELL | 2021-05-24 | $541K | — | Filing → |